Cargando…

Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells and impairment of host immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nuñez Castrejon, Ana M., O’Rourke, Sara M., Kauvar, Lawrence M., DuBois, Rebecca M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Vaccines and Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006937/ https://www.ncbi.nlm.nih.gov/pubmed/35266806 http://dx.doi.org/10.1128/jvi.02201-21

Ejemplares similares

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers
por: Ringe, Rajesh P., et al.
Publicado: (2017)

Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach
por: Aljabr, Waleed, et al.
Publicado: (2016)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells
por: Urbanowicz, Richard A., et al.
Publicado: (2019)

Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines
por: Beck, Yvonne, et al.
Publicado: (2016)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine
por: Law, John L. M., et al.
Publicado: (2018)

Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins
por: Munis, Altar M., et al.
Publicado: (2018)

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
por: Beltran-Pavez, Carolina, et al.
Publicado: (2022)

A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
por: Andersen, Tor Kristian, et al.
Publicado: (2017)

Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination
por: Torrents de la Peña, Alba, et al.
Publicado: (2018)

A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity
por: Dong, Hu, et al.
Publicado: (2021)

Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins
por: Jancovich, James K., et al.
Publicado: (2018)

A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model
por: Ma, Jian, et al.
Publicado: (2023)

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
por: Schiffner, Torben, et al.
Publicado: (2015)

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor
por: Wang, Li, et al.
Publicado: (2021)

Antigenic Characterization of Human Monoclonal Antibodies for Therapeutic Use against H7N9 Avian Influenza Virus
por: Chang, Pengxiang, et al.
Publicado: (2022)

Comparison of the Immunogenicities and Cross-Lineage Efficacies of Live Attenuated Peste des Petits Ruminants Virus Vaccines PPRV/Nigeria/75/1 and PPRV/Sungri/96
por: Hodgson, Sophia, et al.
Publicado: (2018)

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques
por: Jones, Andrew T., et al.
Publicado: (2018)

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex
por: Ha, Sha, et al.
Publicado: (2017)

Inhibitors of Anti-apoptotic Bcl-2 Family Proteins Exhibit Potent and Broad-Spectrum Anti-mammarenavirus Activity via Cell Cycle Arrest at G0/G1 Phase
por: Kim, Yu-Jin, et al.
Publicado: (2021)

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
por: Vigil, Adam, et al.
Publicado: (2018)

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading
por: Gaillard, Vanessa, et al.
Publicado: (2017)

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)

Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response
por: Aljurayyan, Abdullah, et al.
Publicado: (2018)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
por: Coates, Matthew, et al.
Publicado: (2017)

Targeting the Respiratory Syncytial Virus N(0)-P Complex with Constrained α-Helical Peptides in Cells and Mice
por: Galloux, Marie, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice
por: Badamchi-Zadeh, Alexander, et al.
Publicado: (2018)

Development of a Pan-H1 Influenza Vaccine
por: Darricarrère, Nicole, et al.
Publicado: (2018)

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors
por: Abbink, Peter, et al.
Publicado: (2018)

Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model
por: Rosu, Miruna E., et al.
Publicado: (2022)

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL(pro) Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
por: de Vries, Maren, et al.
Publicado: (2021)

Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry
por: Murray, M. J., et al.
Publicado: (2020)

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL(pro) Reporter Assay
por: Froggatt, Heather M., et al.
Publicado: (2020)

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
por: Weston, Stuart, et al.
Publicado: (2020)

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial
por: Lévy, Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfi92sd36oln72qu1qc0kqq9ud